Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 91.14% is in line with its 5-year average of 86.62%, near the high end of its 5-year range (0.00%–96.90%).
0.08% above its 12-month average of 91.06%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 91.58%.
GROSS MARGIN
91.14%
GROSS MARGIN AVG TTM
91.06%
GROSS MARGIN AVG 3Y
89.22%
GROSS MARGIN AVG 5Y
86.62%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.08%
CURRENT VS 3Y AVG
+2.16%
CURRENT VS 5Y AVG
+5.22%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+121.19%
vs the sector median at left
Arcutis Biotherapeutics, Inc.
Market Cap
$2.99B
Gross Margin
91.14%
TTM Avg
91.06%
3Y Avg
89.22%
5Y Avg
86.62%
Market Cap
$3.03B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.06B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
50.00%
5Y Avg
66.67%
Market Cap
$2.88B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.12B
Gross Margin
0.00%
TTM Avg
25.88%
3Y Avg
57.90%
5Y Avg
-575.35%
Market Cap
$3.19B
Gross Margin
90.59%
TTM Avg
93.09%
3Y Avg
93.34%
5Y Avg
78.29%
Market Cap
$2.77B
Gross Margin
58.69%
TTM Avg
59.64%
3Y Avg
63.22%
5Y Avg
64.62%
Market Cap
$2.71B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | $2.99B | 91.14% | 91.06% | 89.22% | 86.62% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.03B | 0.00% | 0.00% | 0.00% | 0.00% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.06B | 0.00% | 0.00% | 50.00% | 66.67% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | 0.00% | 0.00% | 0.00% | 0.00% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.12B | 0.00% | 25.88% | 57.90% | -575.35% |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | 90.59% | 93.09% | 93.34% | 78.29% |
| TransMedics Group, Inc. (TMDX)vs › | $2.77B | 58.69% | 59.64% | 63.22% | 64.62% |
| AtriCure, Inc. (ATRC)vs › | $2.73B | 76.16% | 74.55% | 74.69% | 74.35% |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.71B | 0.00% | 0.00% | 0.00% | 0.00% |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.70B | 17.61% | 20.09% | 39.91% | 58.59% |
Gross Margin
91.1%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 91.58% |
| 2026-03-31 | 90.72% |
| 2025-12-31 | 90.97% |
| 2025-09-30 | 91.25% |
| 2025-06-30 | 90.81% |
| 2025-03-31 | 86.59% |
| 2024-12-31 | 90.32% |
| 2024-09-30 | 87.70% |
| 2024-06-30 | 88.77% |
| 2024-03-31 | 93.43% |
| 2023-12-31 | 83.39% |
| 2023-09-30 | 96.90% |
| 2023-06-30 | 85.05% |
| 2023-03-31 | 71.84% |
| 2022-12-31 | 83.62% |
| 2022-09-30 | 62.90% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
